Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NADINA trial in stage III melanoma
NL-OMON54313Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ipilimumab, nivolumab, dabrafenib + trametinib and trametinib in melanoma and cutaneous malignancy (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival. Started Aug 2021; status: recruiting.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON54313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54313.